Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (521-530 of 755) with videos related to

Pageof 76
Sort By:
Annals of the Rheumatic Diseases|November 9, 2024
Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological studyJohannes Iuel Berg, Sabrina Mai Nielsen, Esben Malm, et al.
Annals of the Rheumatic Diseases|October 16, 2002
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)D E Furst, F C Breedveld, J R Kalden, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 5, 2015
Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosisShervin Assassi, William R Swindell, Minghua Wu, et al.
Annals of the Rheumatic Diseases|October 14, 2004
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004D E Furst, F C Breedveld, J R Kalden, et al.
The Journal of Rheumatology|January 30, 2010
Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritisHaoling H Weng, Veena K Ranganath, Dinesh Khanna, et al.
The Journal of Rheumatology|August 3, 2011
Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working GroupRieke Alten, Christof Pohl, Ernest H Choy, et al.
Annals of the Rheumatic Diseases|October 22, 2005
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005D E Furst, F C Breedveld, J R Kalden, et al.
The Journal of Rheumatology|December 7, 2005
Outcome measures for acute and chronic goutH Ralph Schumacher, Lawrence N Edwards, Fernando Perez-Ruiz, et al.
Arthritis and Rheumatism|May 30, 2006
Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosisRichard A Nash, Peter A McSweeney, J Lee Nelson, et al.
The Journal of Rheumatology|August 18, 2009
Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group)Clifton O Bingham, Christoph Pohl, Thasia G Woodworth, et al.
Pageof 76

Showing results (521-530 of 755) with videos related to

Sort By:
Pageof 76
Annals of the Rheumatic Diseases|November 9, 2024
Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological studyJohannes Iuel Berg, Sabrina Mai Nielsen, Esben Malm, et al.
Annals of the Rheumatic Diseases|October 16, 2002
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)D E Furst, F C Breedveld, J R Kalden, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 5, 2015
Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosisShervin Assassi, William R Swindell, Minghua Wu, et al.
Annals of the Rheumatic Diseases|October 14, 2004
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004D E Furst, F C Breedveld, J R Kalden, et al.
The Journal of Rheumatology|January 30, 2010
Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritisHaoling H Weng, Veena K Ranganath, Dinesh Khanna, et al.
The Journal of Rheumatology|August 3, 2011
Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working GroupRieke Alten, Christof Pohl, Ernest H Choy, et al.
Annals of the Rheumatic Diseases|October 22, 2005
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005D E Furst, F C Breedveld, J R Kalden, et al.
The Journal of Rheumatology|December 7, 2005
Outcome measures for acute and chronic goutH Ralph Schumacher, Lawrence N Edwards, Fernando Perez-Ruiz, et al.
Arthritis and Rheumatism|May 30, 2006
Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosisRichard A Nash, Peter A McSweeney, J Lee Nelson, et al.
The Journal of Rheumatology|August 18, 2009
Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group)Clifton O Bingham, Christoph Pohl, Thasia G Woodworth, et al.
Pageof 76